Prostate Cancer Drugs Global Market Report 2024

The prostate cancer drugs market size has grown strongly in recent years. It will grow from $17.36 billion in 2023 to $18.55 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth observed during the historical period can be attributed to several factors, including an aging population, a higher number of diagnoses, innovations in drug development, increased awareness and education about prostate cancer, and changes in reimbursement and insurance policies.

The prostate cancer drugs market size is expected to see strong growth in the next few years. It will grow to $23.99 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be attributed to factors such as the increasing incidence of prostate cancer, the expansion of markets in emerging regions, supportive government policies, and investments in research and development. Prominent trends in this forecast period include the adoption of precision medicine, advancements in immunotherapy and targeted therapies, the rise of personalized medicine approaches, a focus on clinical trials and drug pipelines, the development of combination therapies, the use of biomarker-driven treatments, as well as the integration of telemedicine and remote monitoring in patient care.

The prostate cancer drugs market is significantly driven by the increasing male geriatric population. Prostate cancer predominantly affects men aged above 60, and the geriatric population is anticipated to grow by 21.6% by 2040, as indicated by the Administration for Community Living (ACL), a US-based government organization. Prostate cancer incidence is higher in older men, with approximately 6 out of 10 cases diagnosed in men aged 65 or older within the geriatric population, according to the American Cancer Society's January 2022 report. Thus, the growing population of elderly men is a key factor fueling the expansion of the prostate cancer drugs market.

The distinct categories of prostate cancer drugs revolve around hormone-sensitive prostate cancer and hormone-refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) represents a form of prostate cancer that no longer responds to hormone therapy, even to more recent treatment approaches. Various therapeutic methods encompass hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and are implemented across diverse healthcare sectors, including hospitals, clinics, and other medical facilities.

The prostate cancer drugs market research report is one of a series of new reports that provides prostate cancer drugs market statistics, including prostate cancer drugs industry global market size, regional shares, competitors with a prostate cancer drugs market share, detailed prostate cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer drugs industry. This prostate cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rising cancer incidence is expected to be a driving force behind the future growth of the prostate cancer drugs market. Cancer is characterized by the uncontrolled growth and division of abnormal cells in the body, and prostate cancer drugs play a crucial role in targeting specific cellular changes that promote cancer cell growth. This differs from traditional chemotherapy and hormone therapy. In January 2023, the American Cancer Society estimated approximately 288,300 new cases of prostate cancer and about 34,700 deaths related to the disease. One in eight men is projected to be diagnosed with prostate cancer during their lifetime. Consequently, the increasing incidence of cancer is a significant driver for the prostate cancer drugs market.

The presence of recurrent or non-responsive prostate cancer poses a substantial constraint to the growth of the prostate cancer drugs market. Recurrent or non-responsive prostate cancer refers to the reoccurrence or spreading of the cancer after initial treatment. This can happen locally in the tissues adjacent to the prostate, nearby lymph nodes in the pelvis, lymph nodes beyond this area, or other organs via the bloodstream. As per the American Society of Clinical Oncology (ASCO), high-risk prostate cancer patients in the US experience recurrence after localized treatment, ranging from 50% to 95%.

An emerging trend in the market is the adoption of combination therapy for the treatment of prostate cancer. This approach is particularly useful in cases where monotherapy proves ineffective. Market companies are increasingly investing in combination therapy, such as the use of XTANDI (enzalutamide) alongside androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer. This combination therapy has demonstrated a significant 71% reduction in the risk of metastasis or death compared to ADT alone. Similar combination therapies include the use of radiation therapy and ADT for men with recurrent prostate cancer and the use of the chemotherapy drug docetaxel (Taxotere) in conjunction with ADT for prostate cancer treatment.

Major companies in the prostate cancer drugs market are striving to introduce new products and gain approvals from regulatory agencies to maximize their market revenues. The process of drug development and approval is intricate and time-consuming, necessitating a thorough understanding of regulatory controls and marketing pathways to ensure safety and effectiveness. For instance, in June 2023, AstraZeneca PLC and Merck & Co. Inc. announced the approval of LYNPARZA (olaparib) Plus Abiraterone and Prednisone or Prednisolone for treating adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) by the United States Food and Drug Administration (USFDA). The approval was based on the significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) demonstrated by LYNPARZA plus abi/pred in comparison to abi/pred alone, as observed in the Phase 3 PROpel trial.

In June 2021, Bayer, a Germany-based pharmaceutical company, made acquisitions of Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc. This strategic move provided Bayer with exclusive access to an alpha radionuclide investigational drug based on actinium-225 and a small molecule targeting prostate-specific membrane antigen. Noria Therapeutics Inc. specializes in the development of alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology, while PSMA Therapeutics Inc. is dedicated to prostate-specific membrane antigen research.

Major companies operating in the prostate cancer drugs market include Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, F. Hoffmann-La Roche AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., GlaxoSmithKline PLC, Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bausch Health Companies Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Agios Pharmaceuticals Inc., Exelixis Inc.

North America was the largest region in the prostate cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The prostate cancer drugs market consists of sales of Abiraterone Acetate, Apalutamide, and Bicalutamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.